A phase Ia/b trial of ARX788 combined with toripalimab for HER2-low advanced breast cancer (ABC) and other HER2-expressing solid tumors

被引：0
|
作者：
Shao, Xiying
Kuang, Ming
Chen, Zhanhong
Zheng, Yabing
Li, Guangliang
Shen, Xia-Bo
Huang, Ping
Cao, Wenming
Xu, Lixia
Wang, Xiaojia
机构：
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Breast Med Oncol, Hangzhou, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Hepatopancreatobiliary Surg, Guangzhou, Peoples R China
[3] Univ Chinese Acad Sci, Canc Hosp, Breast Canc Ctr, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[4] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[5] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China
[6] Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13159
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Preliminary results of GQ1005 in metastatic HER2-low expressing breast cancer and HER2 positive gastric cancer
    Deng, T.
    Sun, Y.
    Wang, B.
    Zhang, J.
    Zhou, C.
    Wang, J.
    Yang, H.
    Yang, B.
    Wei, J.
    Lin, R.
    Liu, J.
    Li, E.
    Ji, Y.
    Wang, L.
    Wang, X.
    Li, Z.
    Yang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S509 - S510
  • [22] Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma
    Zhang, Yang
    Qiu, Miao-Zhen
    Wang, Ju-Feng
    Zhang, Yan-Qiao
    Shen, Ao
    Yuan, Xiang-Lin
    Zhang, Tao
    Wei, Xiao-Li
    Zhao, Hong-Yun
    Wang, De-Shen
    Zhao, Qi
    Xiong, Gao-Zhun
    Ji, Yan-Ping
    Liang, Xue-Jun
    Xia, Gang
    Xu, Rui-Hua
    CELL REPORTS MEDICINE, 2022, 3 (11)
  • [23] Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine
    Kitadai, Rui
    Shimoi, Tatsunori
    Yazaki, Shu
    Okuma, Hitomi Sumiyoshi
    Hoshino, Mai
    Ito, Munehiro
    Saito, Ayumi
    Kita, Shosuke
    Kojima, Yuki
    Nishikawa, Tadaaki
    Sudo, Kazuki
    Noguchi, Emi
    Fujiwara, Yasuhiro
    Yoshida, Masayuki
    Yonemori, Kan
    BREAST CANCER, 2024, 31 (06) : 1037 - 1045
  • [24] Prevalence of HER2-low breast cancer in the GEICAM/2011-06 trial: Agreement in HER2-low classification between standardized immunohistochemistry assays
    Rojo, F.
    Calvo-Martinez, L.
    Bermejo, B.
    Bernet, L.
    Burgues, O.
    Garcia-Caballero, T.
    Lopez-Tarruella Cobo, S.
    Perez, S.
    Antolin-Novoa, S.
    Cejalvo, J. M.
    Jerez Gilarranz, Y.
    Morales Estevez, C.
    Reboredo Rendo, C.
    Martinez, M. T. M.
    Herranz, J.
    Rincon Sanchez, R.
    Caballero, R.
    Barnadas, A.
    De la Haba Rodriguez, J.
    Martin Jimenez, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S332 - S333
  • [25] Analytical validation of Bond Oracle HER2 IHC system for identifying low to intermediate HER2-expressing breast cancer in NeuVax PRESENT phase III clinical trial.
    Jain, Amit K.
    Kumar, Sonia
    Choy, Gavin S.
    Hollemon, Desiree
    Mittendorf, Elizabeth Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] T-DXd for HER2-low expressing cases breast cancer at our hospital
    Noguchi, E.
    Shimizu, Y.
    Nogami, M.
    Tsukada, H.
    Natori, K.
    Aoyama, K.
    Akashi-Tanaka, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S1395 - S1395
  • [27] Advances in research and current challenges in the treatment of advanced HER2-low breast cancer
    Qin, Qiang
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2025, 13
  • [28] Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial
    Wang, Yakun
    Gong, Jifang
    Wang, Airong
    Wei, Jia
    Peng, Zhi
    Wang, Xicheng
    Zhou, Jun
    Qi, Changsong
    Liu, Dan
    Li, Jian
    Lu, Ming
    Lu, Zhihao
    Cao, Yanshuo
    Yuan, Jiajia
    Zhang, Ruyan
    Fang, Jianmin
    Zhang, Xiaotian
    Shen, Lin
    ECLINICALMEDICINE, 2024, 68
  • [29] Updated results and biomarker analyses from the phase I trial of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.
    Hu, Xichun
    Zhang, Jian
    Liu, Rujiao
    Gao, Shuiping
    Wu, Junyan
    Wang, Ying
    Hao, Yanrong
    Ge, Junyou
    Qing, Yan
    Yi, Shuli
    Yang, Qixian
    Rao, Huajing
    Yuan, Juanjuan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] ACE-Breast-03: Efficacy and safety of ARX788 in patients with HER2+metastatic breast cancer previously treated with T-DM1
    Hurvitz, Sara
    Kalinsky, Kevin
    Ganju, Vinod
    Ali, Kashif
    Agrawal, Laila
    Gradishar, William
    Sledge, George
    Thummala, Anu
    Chan, Arlene
    Frentzas, Sophia
    Sohn, Joo Hyuk
    Park, Kyong-Hwa
    Park, Keon Uk
    Shannon, Catherine
    Drago, Joshua
    Tolaney, Sara
    Rugo, Hope
    Press, Michael F.
    Alika, Alex
    Xu, Dong
    Lu, Janice
    Tripathy, Debu
    CANCER RESEARCH, 2023, 83 (05)
12345